Profile data is unavailable for this security.
About the company
Zhejiang CONBA Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of traditional Chinese medicines, modern phytomedicines and chemical drugs. The Company also provides active ingredients. The Company's products include tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye drops, nasal drops, ear drops, ointments and others. Its products are applied in cardiovascular and cerebrovascular diseases, urinary system diseases, digestive diseases, respiratory diseases, endocrine system, nervous system, anti-infection and other treatment areas. The Company also provides value-added services. The Company distributes its products within domestic markets.
- Revenue in CNY (TTM)6.58bn
- Net income in CNY687.99m
- Incorporated1993
- Employees8.26k
- LocationZhejiang CONBA Pharmaceutical Co LtdNo. 568, Binkang Road, Binjiang DistrictHANGZHOU 310052ChinaCHN
- Phone+86 57 187774288
- Fax+86 57 187774722
- Websitehttps://www.conbapharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurisco Pharmaceutical Co Ltd | 1.62bn | 424.54m | 10.37bn | 1.78k | 24.14 | 4.08 | -- | 6.38 | 1.06 | 1.06 | 4.07 | 6.26 | 0.4188 | 1.09 | 4.41 | 910,578.10 | 10.94 | 11.37 | 12.60 | 13.29 | 59.77 | 52.93 | 26.13 | 22.34 | 3.01 | 635.15 | 0.2806 | 31.53 | 16.89 | 20.47 | 22.59 | 13.77 | 49.45 | -- |
| Liaoning Chengda Biotechnology Co Ltd | 1.47bn | 177.94m | 10.65bn | 1.81k | 59.05 | 1.13 | -- | 7.25 | 0.433 | 0.433 | 3.56 | 22.54 | 0.1482 | 0.6786 | 1.24 | 813,192.10 | 1.79 | 8.07 | 1.86 | 8.36 | 79.03 | 84.98 | 12.11 | 35.75 | 19.28 | -- | 0.0013 | 44.77 | -4.22 | -0.0082 | -26.42 | -13.26 | -4.72 | -- |
| Chengdu Olymvax Biopharmaceuticals Inc | 709.13m | 64.21m | 11.12bn | 470.00 | 172.64 | 11.59 | -- | 15.68 | 0.1587 | 0.1587 | 1.75 | 2.36 | 0.3883 | 0.654 | 1.19 | 1,508,792.00 | 3.45 | 3.25 | 5.00 | 4.81 | 92.66 | 93.62 | 8.88 | 8.11 | 1.42 | 8.30 | 0.2906 | 7.39 | 18.69 | 26.88 | 18.24 | -- | 48.00 | -- |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.58bn | 687.99m | 11.29bn | 8.26k | 16.70 | 1.59 | -- | 1.72 | 0.2665 | 0.2665 | 2.54 | 2.80 | 0.6617 | 2.57 | 4.70 | 796,529.00 | 7.13 | 8.51 | 9.65 | 12.74 | 51.88 | 58.64 | 10.77 | 14.12 | 1.38 | -- | 0.0532 | 41.54 | -3.23 | -0.7594 | 5.21 | -- | 1.57 | -- |
| Beijing Foyou Pharma Co Ltd | 3.42bn | 463.07m | 11.47bn | 3.64k | 24.22 | 3.03 | -- | 3.35 | 0.9863 | 0.9863 | 7.28 | 7.87 | 0.733 | 3.27 | 9.59 | 938,316.50 | 9.99 | 12.53 | 12.82 | 17.64 | 65.17 | 68.01 | 13.62 | 13.02 | 2.52 | -- | 0.0077 | 33.16 | 3.17 | 7.28 | -0.0188 | 17.44 | 35.29 | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 3.77bn | 571.60m | 11.50bn | 2.65k | 20.13 | 2.68 | -- | 3.05 | 1.33 | 1.33 | 8.75 | 9.97 | 0.7211 | 6.23 | 11.99 | 1,421,812.00 | 11.38 | 10.77 | 13.82 | 13.35 | 46.77 | 42.40 | 15.78 | 14.39 | 4.58 | -- | 0.0226 | 37.31 | 18.85 | 6.62 | 19.14 | 7.97 | 34.47 | 18.98 |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 2.23bn | 617.04m | 11.90bn | 2.68k | 19.20 | 2.49 | -- | 5.35 | 1.42 | 1.42 | 5.11 | 10.93 | 0.3973 | 2.43 | 9.65 | 830,883.10 | 11.01 | 17.10 | 11.88 | 21.16 | 43.04 | 42.99 | 27.72 | 30.12 | 4.31 | -- | 0.0721 | 24.41 | 17.35 | 1.75 | 36.85 | -2.20 | 35.06 | -- |
| Cansino Biologics Inc | 971.83m | -142.03m | 12.00bn | 1.11k | -- | 3.32 | -- | 12.35 | -0.5455 | -0.5455 | 3.92 | 21.37 | 0.1271 | 0.5861 | 1.38 | 879,482.50 | -1.86 | -4.08 | -2.29 | -5.38 | 78.80 | 45.31 | -14.62 | -27.51 | 3.29 | -- | 0.2242 | -- | 137.01 | 226.43 | 74.45 | -- | 31.38 | -- |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 9.84bn | 546.80m | 12.25bn | 7.99k | 21.39 | 1.44 | -- | 1.25 | 0.4778 | 0.4778 | 8.61 | 7.10 | 0.623 | 3.08 | 5.32 | 1,230,310.00 | 3.48 | 2.33 | 5.81 | 4.32 | 46.64 | 41.26 | 5.58 | 3.99 | 0.6646 | 5.33 | 0.2803 | 29.47 | -5.65 | -2.44 | 745.24 | 45.22 | -26.03 | 33.24 |
Data as of Mar 03 2026. Currency figures normalised to Zhejiang CONBA Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
3.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 16.70m | 0.66% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 11.14m | 0.44% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2025 | 10.59m | 0.42% |
| Orient Securities Asset Management Co. Ltd.as of 30 Jun 2025 | 9.48m | 0.38% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 8.77m | 0.35% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 8.42m | 0.34% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2025 | 7.83m | 0.31% |
| The Vanguard Group, Inc.as of 31 Jan 2026 | 7.46m | 0.30% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 4.49m | 0.18% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 3.34m | 0.13% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
